Endogenous folate stores are required in preimplantation embryos of several species, but how folates are accumulated and whether they can be replenished has not been determined. Folates are generally taken up into cells by specific transporters, mainly the reduced folate carrier RFC1 (SLC19A1 protein) and the high-affinity folate receptors FOLR1 and FOLR2. Quantitative RT-PCR showed that Slc19a1 mRNA was expressed in mouse cumulus-oocyte complexes (COCs) and oocytes, whereas Folr1 showed expression only in preimplantation embryos, increasing from the 2-cell stage onward. The mRNAs encoding Folr2 and the intestinal folate transporter Slc46a1 were not detected. Methotrexate (MTX), an antifolate often used as a model substrate for folate transport, exhibited saturable transport in COCs and in preimplantation embryos starting at the 2-cell stage. However, folate transport characteristics differed between COCs and embryos. In COCs, transport of MTX and the reduced folate leucovorin was inhibited by the anion transport inhibitor SITS that blocks RFC1 but was insensitive to dynasore, a specific dynamin inhibitor that instead inhibits folate receptor-receptor mediated endocytosis, whereas the opposite was found in 2-cell embryos and blastocysts. The inhibitor profile and transport properties of MTX and leucovorin in COCs correspond to established transport characteristics of RFC1 (SLC19A1), whereas those in 2-cell embryos and blastocysts correspond with those of FOLR1, consistent with the mRNA expression patterns. Considerable folate was accumulated in COCs via RFC1, but the presence of cumulus cells did not enhance folate accumulation in the enclosed oocyte, indicating a lack of transfer from cumulus to oocyte.
INTRODUCTION
The main mechanism of 1-carbon (1C) metabolism in most cells uses folates as carriers of 1C units as they are transferred from donors onto a wide variety of substrates [1, 2] . In the folate cycle, the 1C methyl group is removed from 5-methyltetrahydrofolate (5-methyl-THF) and transferred onto homocysteine to yield tetrahydrofolate (THF) and methionine. THF is then recycled by transfer of a methyl group from serine to form 5,10-methylene-THF followed by reduction back to 5-methyl-THF [2] . Methyl groups are thus shuttled from serine to methionine each time the cycle is repeated. The methionine produced by remethylation of homocysteine is the only significant source in most cells of the universal methyl donor S-adenosylmethionine (SAM) that serves as the substrate for most methyltransferase reactions and for polyamine synthesis [3] ; the intermediate 5,10-methylene-THF is the methyl donor for thymidine synthesis or is further metabolized into the formate donor for purine synthesis [2, 4] . In each case, 1C donors are metabolized, but the folates are conserved and recycled back into the folate cycle.
Despite recycling, cells must initially accumulate a pool of folates and replenish folates that are degraded or lost from the cells. Folates are not synthesized by mammals but are instead obtained through the diet via a specialized intestinal transporter that functions to absorb dietary folates. This transporter, the proton-coupled folate transporter (PCFT), requires low extracellular pH, because it relies on an inward H þ gradient. The SLC46A1 protein (Slc46a1 gene) underlies PCFT activity [5] . The predominant form of bioavailable folate in the mammalian circulation is 5-methyl-THF, which is either taken up directly from dietary sources or produced by metabolism of dietary folic acid, both of which involve absorption in the intestine via the PCFT [5, 6] .
In most cells, the major routes of folate uptake from extracellular fluids are the reduced folate carrier (RFC1) and folate receptors. A single gene, Slc19a1, encodes the SLC19A1 protein that has RFC1 activity [7, 8] . Several forms of folate receptors exist, with humans and mice having orthologous genes encoding FOLR1 and FOLR2 (FRa and FRb, respectively), with an additional gene for FOLR3 (FRc) in humans [9, 10] . RFC1 and folate receptor activities often coexist in the same cells but can be clearly distinguished by their distinct physiological properties. First, RFC1 is an antiporter that binds folates and transfers them into the cell in exchange for inorganic phosphate [10, 11] ; in contrast, folate receptors on the external cell surface bind folates with high affinity and then are endocytosed, with the folates released from the receptor within the cell by low pH in endocytic organelles [12, 13] . Thus, acute inhibition of endocytosis blocks folate transport by folate receptors but not by RFC1. Second, their substrate specificities differ, with SLC19A1 (RFC1) having a high affinity (micromolar range) for reduced folates (e.g., THF, 5-methyl-THF, and the analog 5-formyl-THF, also known as folinic acid or leucovorin) but an affinity at least two orders of magnitude lower for folic acid, whereas folate receptors have extremely high affinities (nanomolar range) for both folic acid and reduced folates [14, 15] . SLC19A1 (RFC1) has an affinity for the widely used antifolate methotrexate (MTX) approximately equal to its affinity for reduced folates, whereas folate receptors have an affinity one to two orders of magnitude lower for MTX than for folic acid or reduced folates [14] [15] [16] . Finally, the stilbene 4-acetamido-4 0 -isothiocyanato-stilbene-2,2 0 -disulfonic acid (SITS), a broadly active inhibitor of anion transport, effectively blocks transport via SLC19A1 (because it is an anion antiporter) but is ineffective against folate receptormediated transport [14] .
As recently comprehensively reviewed by Ikeda et al. [17] , mammalian oocytes and preimplantation embryos likely have fully functional 1C metabolism, because they express all of the enzymes needed for 1C metabolism, at least at the mRNA level. In particular, folate cycle enzyme mRNAs are expressed by bovine oocytes and preimplantation embryos [18, 19] , human oocytes [20] , and human embryonic stem cells that are analogous to inner cell mass cells of the blastocyst [21] . At least part of the 1C metabolic pathway is functional, both because methionine is converted to SAM in mouse and human oocytes and mouse embryos [22] and because blocking conversion of methionine to SAM inhibits mouse and bovine preimplantation embryo development [22] [23] [24] .
Folate metabolism appears to be functional and required in preimplantation embryos. The antifolate MTX, which blocks dihydrofolate folate reductase and folate-dependent enzymes in thymidine and purine synthesis as well as folate transporters, inhibits murine, bovine, and ovine preimplantation embryo development. The MTX-induced arrest of embryo development can be substantially rescued by adding purines and thymidine to culture [19, 25] . It was proposed that the folates required in oocytes and preimplantation embryos are endogenous, both because in vitro embryo development has no absolute requirement for exogenous folates and because MTX effectively inhibits development in the absence of any folates in the medium [19, 25] . It is, however, unclear whether oocytes and preimplantation embryos normally accumulate folates from their extracellular environment in vivo, despite being able to survive without exogenous folates in vitro. Similarly, in this regard, no absolute requirement exists for any amino acids during preimplantation embryo development in vitro, but embryo developmental potential is substantially improved by amino acids in culture that are transported into the cells [26, 27] .
Folate transport may indeed be functional before implantation, because bovine oocytes and preimplantation embryos express SLC19A1 mRNA, SLC19A1 (RFC1) protein, and FOLR1 (but not FOLR2) mRNA [19] . Folate transporter expression in oocytes and preimplantation embryos has only been examined qualitatively, by conventional RT-PCR and by immunofluorescence in the case of bovine SLC19A1; thus, developmental changes in expression levels have not been elucidated. More importantly, the transport of folates by mammalian oocytes or preimplantation embryos has not been investigated, so it is unknown whether they can replenish their pool with exogenous folates at any stage or how the initial accumulation of endogenous folates can occur. Therefore, we examined the quantitative expression of folate transporter mRNA in mouse cumulus-oocyte complexes (COCs), oocytes, and preimplantation embryos and determined whether the related routes of folate transport were active in mouse COCs, oocytes, and embryos.
MATERIALS AND METHODS

Chemicals and Solutions
All chemicals were obtained from Sigma-Aldrich Canada Ltd. unless otherwise specified. Culture media components were embryo tested or cellculture grade. The modified potassium simplex optimized medium (KSOM) for mouse embryos [28] contained 95 mM NaCl, 2.5 mM KCl, 0.35 mM KH 2 PO 4 , 0.2 mM MgSO 4 , 10 mM sodium lactate, 0.2 mM glucose, 0.2 mM sodium pyruvate, 25 mM NaHCO 3 , 1.7 mM CaCl 2 , 0.01 mM tetrasodium ethylenediaminetetra-acetic acid, 0.03 mM streptomycin sulfate, and 0.16 mM penicillin G. This differs from unmodified KSOM in that glutamine was omitted and polyvinyl alcohol (1 mg/ml) was substituted for bovine serum albumin as the macromolecular component. Where specified, we incubated COCs overnight in modified Eagle minimum essential medium alpha (MEMa), which was made in-house to have the same composition as our usual COC culture medium (MEMa from Life Technologies/Gibco, catalog no. 12561) except that folic acid was omitted. HCO 3 À /CO 2 -buffered media were equilibrated with 5% CO 2 in air. HEPES-KSOM (21 mM HEPES replacing equimolar NaHCO 3 , pH adjusted to 7.4) was used for embryo collection.
COC, Oocyte, and Preimplantation Embryo Collection
Animal protocols were approved by the Animal Care Committee of the Ottawa Hospital Research Institute. COCs, oocytes, and embryos were obtained as previously described [29, 30] from female CF1 (Crl:CF1) mice (age, 4-6 wk; Charles River) that had been superovulated by intraperitoneal injection with 5 IU of equine chorionic gonadotropin (eCG; Intervet). COCs containing fully grown germinal vesicle (GV) oocytes were collected from mechanically minced ovaries 44-46 h after eCG administration. For denuded GV oocytes, cumulus cells were removed by repeated pipetting through a narrow-bore pipette. For mature metaphase II (MII) eggs and embryos, 5 IU of human chorionic gonadotropin (hCG) were injected intraperitoneally 47.5 h after eCG administration. MII oocytes were collected from excised oviducts approximately 15 h after hCG administration. For embryos, the females were caged immediately after hCG administration with BDF1 (B6D2F1/Crl) males (Charles River) overnight for mating. Embryos were removed from excised oviducts (1-cell, 2-cell, or 8-cell stage) or from oviducts with uterine horns attached (morula stage) by flushing with HEPES-KSOM at the following times after hCG administration: 1-cell embryos, approximately 21 h; 2-cell embryos, approximately 44 h; 4-cell embryos, approximately 56 h; 8-cell embryos (uncompacted), approximately 67 h; morulae (compacted), approximately 76 h; and blastocysts, approximately 94 h. MII eggs and 1-cell embryos were freed from residual cumulus matrix by brief exposure to 300 lg/ml of hyaluronidase followed by rinsing four times. Fertilization was confirmed in 1-cell embryos by the presence of two pronuclei. GV oocytes were maintained in meiotic arrest during collection and transport measurements by inclusion of 300 lM dbcAMP for isolated GV oocytes and 100 nM natriuretic peptide precursor type C (NPPC) plus 100 nM estradiol for intact COCs [31, 32] .
Reverse Transcription-Polymerase Chain Reaction
Both RT-PCR and quantitative RT-PCR (Q-RT-PCR) were performed as previously described [33] . Briefly, total RNA was extracted from three independent sets of oocytes, preimplantation embryos, and kidney as control and reverse-transcribed groups. [34, 35] . The RT-PCR and Q-RT-PCR conditions used in the present study are as previously described [33] . Each PCR reaction contained 0.15 equivalent of embryo, oocyte, or COC cDNA in a 20-ll reaction volume. The number of transcripts reported for Q-RT-PCR was calculated from standard curves constructed using known dilutions of PCR product. H(N)]-(6S)-leucovorin; 10-40 Ci/mmol) were obtained from Moravek Biochemicals and Radiochemicals. The appropriate volume of radiolabeled chemical was evaporated for 1 h and allowed to redissolve in medium for 3 h at room temperature, followed by at least 2 h of equilibration at 378C in 5% CO 2 in air before transport experiments were performed.
Radiolabeled Compound Transport Measurements
Transport of radiolabeled compounds was measured by methods previously described in detail [36] and used extensively in COCs, oocytes, and preimplantation embryos [29, [37] [38] [39] . Briefly, COCs, oocytes, or preimplantation embryos were transferred into pre-equilibrated medium containing the radiolabeled compound for the specified length of time, then washed five times in ice-cold medium and immediately transferred to scintillation vials with scintillation fluid (4 ml). The amount of 3 H-labeled compound used was 2 lM for MTX and leucovorin and 5 lM for folic acid. Where unlabeled compound or other possible competitive inhibitors were present, they were included at 500-fold excess over the low concentration of 3 H-labeled substrate, which ensures nearly complete inhibition over a wide range of transport affinities [39, 40] . A similar volume of the last wash drop was transferred to a separate vial and treated identically to obtain background that was subtracted from each paired measurement. Each sample was counted for 5 min. Conversion of counts per minute to molar amounts of labeled compound was done using a standard curve constructed for each set of experiments by serial dilutions in water. Measurements were done using an liquid scintillation counter (LS6500; Beckman Coulter, Inc.). The amount of radiolabeled compound was expressed as femtomoles per COC, oocyte, or embryo. For experiments in which the effect of the inhibitor dynasore on transport was tested, COCs or embryos were preincubated with dynasore or 0.1% dimethyl sulfoxide (vehicle) for 30 min before being transferred into the medium with radiolabeled compound in the continued presence of dynasore. Transfer of compounds taken up by intact COCs into the enclosed GV oocytes was determined as previously described for amino acids [29] . Briefly, intact COCs and denuded GV oocytes were incubated together in medium with radiolabeled compound, after which the total amount of radiolabeled compound taken up was measured in intact COCs, GV oocytes removed from the COCs after the incubation period, and GVs that were denuded before incubation. Enhancement of compound uptake by the presence of cumulus would thus be revealed by higher amounts of the compound in GV oocytes that had been enclosed in COCs during incubation versus those that had been denuded of cumulus [29, 41] .
Data Analysis
Data were expressed as the mean 6 SEM. Means were compared by ANOVA with Tukey post hoc test for multiple (n . 2) comparisons, or Student two-tailed t-test for comparing two means, using GraphPad Prism (GraphPad Software, Inc.). Where a single cohort was distributed into all treatment groups for each repeat, paired ANOVA or Student t-test was used, as specified. Differences were assumed to be significant at P , 0.05. Data were plotted using GraphPad Prism.
RESULTS
Expression of Folate Transporter mRNAs
We first screened for expression of folate transporter mRNAs in intact mouse COCs, GV oocytes, MII eggs, and preimplantation embryos from the 1-cell through blastocyst stages using conventional RT-PCR. Bands were detected for the reduced folate carrier Slc19a1 in COCs and oocytes, with a fainter band in blastocysts, and for the folate receptor Folr1, with the strongest band in blastocysts (Fig. 1A) . No expression was apparent for Folr2 and only faint bands for the intestinal PCFT Slc46a1. The identities of representative bands for Slc19a1 and Folr1 were confirmed by sequencing (not shown). Expression was then quantified for Slc19a1 and Folr1 mRNAs using Q-RT-PCR. Slc19a1 showed the highest expression in COCs and oocytes. In contrast, Folr1 expression started at approximately the 2-cell stage and was highest in blastocysts (Fig. 1B) . Because a faint band had been detected, a single Q-RT-PCR was performed for Slc46a1; however, no signal was obtained by Q-RT-PCR up to 35 cycles (not shown). Q-RT-PCR was not performed for Folr2, because no bands had been detected with conventional RT-PCR. Thus, the reduced folate 
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carrier Slc19a1 and folate receptor Folr1 showed complementary quantitative expression patterns, with the carrier predominant in COCs and oocytes and the receptor expressed most highly at the end of preimplantation development. We were not able to confirm that the mRNA expression patterns corresponded to protein expression, because available antisera against SLC19A1 and FOLR1 did not yield consistent, specific results in Western blots.
Folate Transport
Methotrexate is commonly used as a model substrate for folate transporters, because it is not metabolized and has comparable affinity for both the reduced folate transporter and folate receptors. For this, it functions as a folate analog rather than in its more commonly known role as an antifolate that inhibits enzymes in the folate cycle. Because MTX is not metabolized, its uptake is not affected by its interaction with folate cycle enzymes. In addition, acute transport experiments would not be affected by any long-term effects of MTX on endogenous folate metabolism. The total amount of [ 3 H]MTX taken up by mouse COCs, GV oocytes, MII eggs, and preimplantation embryos was measured after 20 or 90 min, and the amount of nonsaturable (nonspecific) uptake was determined as the residual uptake in the presence of a 500-fold excess of unlabeled MTX. Significant saturable transport was evident in COCs and in preimplantation embryos starting at the 2-cell stage but not in oocytes or eggs ( Fig. 2A) . A more detailed measurement of MTX uptake versus time in 2-cell embryos revealed that saturable uptake plateaued by 90 min and indicated that the ratio of total to nonsaturable uptake was best for detection at this time (Fig. 2B ), whereas 20 min had been sufficient to easily detect saturable uptake in COCs ( Fig.  2A) . Similar, more detailed time courses were also obtained for GV oocytes and intact COCs (see below).
The characteristics of transport in COCs were probed using several possible inhibitors. The specific, saturable component of [ 3 H]MTX transport was eliminated by 500-fold excess of folic acid or the reduced folate leucovorin (folinic acid) or by SITS (Fig. 3A) . Similarly, saturable transport of [ 3 H]leucovorin in COCs was inhibited by 500-fold excess of MTX and by SITS, whereas folic acid showed only a trend toward inhibition (Fig. 3A) . Transport of leucovorin (2 lM) was approximately 2-fold higher than that of the same concentration of MTX in COCs. In contrast, MTX showed only a trend toward inhibition of [ 3 H]leucovorin uptake at the 2-cell and blastocyst stages, whereas folic acid was more effective, particularly in blastocysts, and SITS had no effect (Fig. 3B ). Finally, [ 3 H]folic acid transport was assessed at each stage. No saturable transport of folic acid was detectable in COCs, where a 200-fold excess of unlabeled MTX had no effect, but a trend was observed toward inhibition in 2-cell embryos and variable but larger uptake in the absence of unlabeled folic acid in blastocysts (Fig. 3C) .
We next determined the effect of inhibiting endocytosis with dynasore, a specific small-molecule inhibitor of dynamin GTPase [42, 43] [42, 43] and thus should prevent folate uptake by receptor-mediated endocytosis via FOLR1 or FOLR2. Dynasore (80 lM) had no effect on either MTX or leucovorin transport in COCs, but it substantially blocked transport of either compound in both 2-cell embryos and blastocysts (Fig. 4) .
Transfer of Folates from Cumulus Cells to the Enclosed Oocyte
Because specific saturable folate transport occurred in intact COCs but not denuded GV oocytes, we hypothesized that folates might be taken up by cumulus cells and transferred to the enclosed oocyte via gap junctions. We thus compared the amounts of [ 3 H]MTX taken up by entire intact COCs, GV oocytes denuded of cumulus cells before incubation with [ 3 H]MTX, and GV oocytes that had been enclosed in COCs during incubation and denuded afterward. Denuded GV oocytes were maintained in arrest with dbcAMP, whereas COCs were incubated with NPPC and estradiol to maintain physiological arrest. The total amount of MTX that was accumulated plateaued, with approximately twice as much total MTX taken up by entire COCs as by denuded GV oocytes. Being enclosed within the COC, however, virtually eliminated MTX accumulation in the GV oocyte (Fig. 5A) , indicating that uptake of MTX into GV oocytes was not enhanced by transfer from the surrounding cumulus during incubations of up to 3 h.
It was not possible to measure transport of MTX for substantially longer than 3 h due to its toxicity. We therefore used [ 3 H]leucovorin to determine whether this reduced folate could be transferred to the enclosed oocyte over 24 h. COCs accumulated a considerable amount of 3 H-label from leucovorin after 24 h, but very low amounts of 3 H-label were found in GV oocytes that had been enclosed during this time, with no difference in the amount of leucovorin-derived 3 H-label accumulated by denuded versus enclosed oocytes (Fig. 5B) . The coupling index for leucovorin, which measures of the accumulation enhancement of a substrate by transfer from cumulus to enclosed oocyte ([A À B]/B, where A ¼ substrate accumulated in and enclosed oocyte and B ¼ substrate accumulated by a denuded oocyte) was À0.15, indicating slight inhibition of accumulation in enclosed oocytes. By convention, values of the coupling index that lie within the range of À0.5 to 0.5 (i.e., 50% inhibition or enhancement) are considered not to be significantly different than zero [29. 44, 45] ; thus, the presence of the cumulus had no effect on leucovorin uptake by oocytes over 24 h.
DISCUSSION
The qualitative folate transporter mRNA expression patterns for mouse oocytes and preimplantation embryos essentially agree with results previously reported for cow. Conventional RT-PCR indicated that bovine SLC19A1 mRNA is detected in oocytes and blastocysts [19] , similar to the pattern we found in the mouse. Our quantitative measurements, however, revealed that high expression of murine Slc19a1 was restricted to COCs and oocytes; expression was much lower in blastocysts. Qualitatively, bovine FOLR1 mRNA detection was restricted to embryos from the 8-cell stage onward [19] , with a fainter band in oocytes, again consistent with the pattern we found in the mouse with conventional RT-PCR. Our quantitative data for Folr1 confirmed that high expression was restricted to the later preimplantation stages in mouse, with monotonically increasing expression from the 2-cell through blastocyst stages. Finally, as for the bovine ortholog, murine Folr2 was absent from all stages of oocyte and preimplantation embryo [19] . Thus, murine oocytes and embryos appear to have developmental patterns of folate transporter expression very similar to those reported for bovine. Human embryonic stem cells, which are analogous to the blastocyst inner cell mass, express FOLR1 but not FOLR2 [21] , consistent with the FOLR mRNA expression pattern in the mouse and bovine blastocyst KOOISTRA ET AL. . NPPC (100 nM) and estradiol (100 nM) were added to COC medium, and dbcAMP (300 lM) was added to GV medium, to maintain GV arrest. Each point represents the mean 6 SEM of five repeats. B) Total amount of MTX was measured as in A for 2-cell embryos but with additional time points up to 180 min. Symbols indicate total and nonsaturable MTX uptake as in A. In both A and B, differences between means of total and nonsaturable amounts of MTX at the same time point were examined by Student t-test (*P , 0.05, **P , 0.01, ***P , 0.001).
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(SLC19A1 was not assessed in human embryonic stem cells). It remains to be determined, however, whether folate transporter expression in human oocytes and embryos at each stage is similar to that of mouse and cow.
Endogenous folates almost certainly play a role in preimplantation development. O'Neill and others have concluded that endogenous folates are sufficient in the preimplantation period, because MTX (acting as an antifolate to inhibit the folate cycle) is able to block embryo development in the absence of exogenous folates in vitro, embryos develop without folates in culture media, and adding folic acid does not improve preimplantation embryo development in vitro [17, 25] . Nevertheless, the endogenous folate pool must be accumulated and possibly replenished from external sources, which likely involve specific transport into the oocyte or embryo. The size of the endogenous folate pool in oocytes or embryos is unknown. Somatic cells have approximately 1 lM intracellular folate [46] . Follicular fluid has on the order of 0.5 nmol folate/g total protein [47] , which, assuming 6 g/dl of total protein in follicular fluid [48] , corresponds to approximately 0.03 lM. Thus, facilitated accumulation of folates into oocytes or embryos up its transmembrane gradient likely occurs at some point during development.
The present findings are consistent with two distinct folate transport mechanisms being present in COCs versus preimplantation embryos-namely, RFC1-type transport by SLC19A1 in COCs and folate receptor-mediated endocytosis via FOLR1 in preimplantation embryos from the 2-cell through blastocyst stages. The assignment of folate transport in COCs to RFC1 activity is consistent with the high expression of Slc19a1 mRNA. Transport measurements in COCs revealed a preference for the reduced folate analog leucovorin over MTX, relatively poor inhibition by folic acid and lack of saturable folic acid transport, inhibition by SITS, and lack of effect when endocytosis was blocked, all of which are consistent with SLC19A1 transport properties. However, this activity was only found in intact COCs; it was not detectable in denuded GV oocytes or in MII eggs or preimplantation embryos at any stage assessed. This was unexpected given the presence of Slc19a1 transcripts in oocytes but was clearly indicated by the transport measurements. It remains to be determined whether the Slc19a1 mRNA apparently present in oocytes remains untranslated or whether SLC19A1 protein is not functional. It is also possible that the mRNA detected actually originates in cumulus remnants that remain with the isolated oocyte.
The folates transported into the COC were not detectably transferred to the enclosed oocyte, either over several hours (using MTX) or over 24 h (using leucovorin), because no increase was found in the amount of these folate analogs in enclosed GV oocytes versus isolated oocytes. This is in contrast to a number of compounds, including metabolic substrates, amino acids, choline, and uridine, for which accumulation in GV oocytes is substantially facilitated even during short incubations by coupled cumulus cells [29, 44, 45, 49] . Therefore, we conclude that RFC1 transport mediated by SLC19A1 protein is present only in the cumulus compartment of COCs and does not act to provide the fully grown GV oocyte with folate. Thus, its function is likely to supply cumulus cells with folate.
In contrast to COCs, folate transport starting at the 2-cell stage appears to be due to the folate receptor FOLR1. This is consistent with Folr1 transcript expression starting at that stage. The transport characteristics in 2-cell embryos and blastocysts, including relative insensitivity of leucovorin transport to MTX but inhibition by folic acid, insensitivity to SITS, and a trend toward saturable folic acid transport, are consistent with FOLR1 transport. The key property, however, that identifies this folate transport as due to FOLR1 is the complete inhibition when endocytosis was prevented with dynasore. Thus, we conclude that starting at approximately the 2-cell stage, preimplantation embryos are capable of taking up folates from the external environment via FOLR1 endocytosis. Folr1 is apparently a product of the embryonic genome, because it arises at the major zygotic genome activation in H]leucovorin (right) was assessed in COCs, 2-cell embryos, and blastocysts in the presence or absence of the dynamin GTPase inhibitor dynasore (80 lM) in KSOM. Vehicle only (0.1% dimethyl sulfoxide) was present in control. COCs and embryos were pretreated with dynasore or vehicle for 30 min before transport was measured in the continued presence of dynasore. Total incubation time with radiolabeled compounds was 20 min except for MTX in 2-cell embryos and blastocysts, where 90 min was used. Bars represent the mean 6 SEM of five repeats. Difference between means with or without dynasore was tested by paired Student t-test (*P , 0.05, ***P , 0.001, NS ¼ not significant).
mouse at the 2-cell stage. Similarly, FOLR1 likely is a product of the embryonic genome in bovine embryos, because it appears at the 8-cell stage [19] , when the bovine zygotic genome activation occurs.
Whether an endogenous pool of folate exists in oocytes and 1-cell embryos before specific transport arises and, if so, what is its origin remain open questions. The arrest of 1-cell embryos cultured for 20 h with MTX reported by O'Neill [25] seems to indicate that endogenous folate is already present in 1-cell mouse embryos. If so, it may be accumulated during oocyte growth and already be present in fully grown GV oocytes. In bovine and ovine embryos, MTX did not cause arrest until the 8-cell stage [19] , which could imply that folates are not present or required before this stage but, conversely, could indicate that enough of each folate in the folate cycle is stockpiled so that blocking the folate cycle has no effect. Measurements of the endogenous folate pool in oocytes and each stage of preimplantation embryo would help to resolve the question of when the folate pool is established. Clearly, however, preimplantation mouse embryos have the capacity to accumulate additional folate via FOLR1-mediated uptake beginning at the 2-cell stage. This may serve to replenish endogenous pools with external folate and maintain them at optimal levels for preimplantation embryo development and the production of a healthy fetus and placenta. However, how significantly the capacity to accumulate folates contributes to maintaining the total folate pool in later-stage preimplantation embryos remains to be investigated.
